Detalhe da pesquisa
1.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447003
2.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet
; 402(10409): 1272-1281, 2023 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708904
3.
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4073-4083, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38459418
4.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer
; 153(1): 153-163, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883420
5.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982686
6.
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Oncologist
; 25(8): e1181-e1187, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32311799
7.
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial.
BMC Cancer
; 20(1): 122, 2020 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32059704
8.
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4121-4122, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575722
9.
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
BMC Cancer
; 17(1): 893, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29282088
10.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776843
11.
Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses.
Cancer Discov
; 13(10): 2192-2211, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37489084
12.
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Nat Commun
; 14(1): 5032, 2023 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596280
13.
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Eur J Cancer
; 165: 48-57, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35202974
14.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
J Clin Oncol
; 40(32): 3750-3761, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709415
15.
Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
Am Soc Clin Oncol Educ Book
; 39: e88-e95, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31099690